articles
Figure2.Schematicdiagramillustratingtheprocessofthe
trainingapredictionmodelandusingitforpredictingactivecompoundsofacompoundclassfromtheirstructurallyderivedproperties(moleculardescriptors)byusingsupportvectormachines.A,B,E,Fand(hj,pj,vj,...)representsuchstructuralandphysicochemicalpropertiesashydrophobicity,volume,polarizability,

etc.
EGFR-FGFR,112,1,262and748forEGFR-Src,61,1,232and445forVEGFR-Lck,230,450,and233forPDGFR-FGFR,188,492,and672forPDGFR-Src,56,804,and450forSrc-Lck,174,484,and650forCDK1-CDK2,155,503,and642forCDK1-GSK3,75,749,and722forCDK2-GSK3,and41,651,and1285forCDK1-VEGFRrespec-tively.Thedual-inhibitorsandnon-dual-inhibitorsaredis-tributedin17-84and90-427familiesrespectively.Hence,boththenumbersanddiversityofnon-dual-inhibitorsanddual-inhibitorsareatreasonablelevelsfordevelopingandtestingVStools.Thepercentagesofdual-inhibitorsoutsidethecommonfamiliesofthenon-dual-inhibitorsinthetrainingdatasetsare62.1%forEGFR-PDGFR,57.9%forEGFR-FGFR,58.9%forEGFR-Src,52.5%forVEGFR-Lck,60.9%forPDGFR-FGFR,62.2%forPDGFR-Src,58.9%forSrc-Lck,69.5%forCDK1-CDK2,68.4%forCDK1-GSK3,58.7%forCDK2-GSK3,and82.9%forCDK1-VEGFRrespectively.Therefore,thesedual-inhibitorshaveasub-stantialdegreeofnoveltyagainstnon-dual-inhibitors.More-over,0.0%-98.6%ofthedual-inhibitorsofthekinasepairsareinhibitorofatleastoneoftheother7kinases,butonly
1552
MOLECULARPHARMACEUTICSVOL.7,NO.5
Maetal.
Figure3.Top6scaffoldscontainedinhigherpercentages
ofthedual-inhibitorsofthestudiedintra-PTKgroupkinasepairs.
upto5.2%ofthedual-inhibitorsareinhibitorsofatleast3oftheother7kinases.Hence,mostofthesedual-inhibitorsarenonubiquitousinhibitorsandshowsomedegreeofkinaseselectivityeventhoughthemajorityofthemtargetmorethan2kinases.
Somedistinguishingfeaturesofdual-inhibitorsmaybeprobedbyevaluatingthetop6scaffoldscontainedinhigherpercentagesofthedual-inhibitorsofthestudiedintra-PTKgroupkinasepairs,whichareshowninFigure3.Table3showsthedistributionofthesescaffoldsinthedual-inhibitorsandnon-dual-inhibitorsofthestudiedintra-PTKgroupkinasepairs.ScaffoldAiscontainedin63.8%ofEGFR-PDGFR,76.1%ofPDGFR-Src,33.9%ofEGFR-Src,54.9%ofEGFR-FGFRand27.8%ofVEGFR-Lckdual-inhibitorsrespectively;scaffoldBiscontainedin57.1%ofSrc-Lck,29.5%ofVEGFR-Lckand25.9%ofEGFR-Srcdual-inhibitorsrespectively.ScaffoldAandscaffoldBappeartobethebackboneofmajorityofdual-inhibitorsofthestudiedkinasepairs.ScaffoldCismainlycontainedin19.6%ofEGFR-Srcdual-inhibitors.ScaffoldDismainlycontainedin32.4%inEGFR-FGFRand4.5%inEGFR-Srcdual-inhibitors.ScaffoldEiscontainedin17.8%ofPDGFR-FGFR,8.6%ofEGFR-PDGFR,7.0%ofEGFR-FGFRand6.9%ofPDGFR-Srcdual-inhibitors.ScaffoldFiscontainedin37.5%ofSrc-Lckand34.4%ofVEGFR-Lckdual-inhibitors.Thesescaffoldsarealsocontained,mostlyatsigni cantlylowerpercentagelevels,inthenon-dual-inhibitorsofatleastoneofthekinasesoftherespectivekinasepairs.Therefore,somespeci cvariationsofside-chaingroupsofthesescaffoldsappeartobesuf cienttoconvertsomedual-inhibitorsintonon-dual-inhibitors,whichsuggeststhatphysicochemicalpropertiesaswellasstructuralfeaturesareimportantfordistinguishingdual-and

non-dual-inhibitors.
Synthesis and Characterization of Pyrazoleanthrone Derivatives as Aurora A Kinase Inhibitors_生产/经营管理_经管营销_专业资料。Chem.Res.Chin.Univ.2013.29(6)...
Synthesis and Characterization of Pyrazoleanthrone Derivatives as Aurora A Kinase Inhibitors_生产/经营管理_经管营销_专业资料。Chem.Res.Chin.Univ.2013.29(6)...
热门文档